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Abstract
Therapeutic compensation of deficient bone regeneration 
is a challenging task and a topic of on-going search for 
novel treatment strategies. One promising approach for 
improvement involves non-viral gene delivery using the 
bone morphogenetic protein-2 (BMP-2) gene to provide 
transient, local and sustained expression of the growth 
factor. However, since efficiency of non-viral gene delivery 
is low, this study focused on the improvement of a BMP-
2 gene expression system, aiming for compensation of 
poor transfection efficiency. First, the native BMP-2 gene 
sequence was modified by codon optimisation and altered 
by inserting a highly truncated artificial intron (96 bp). 
Transfection of multiple cell lines and rat adipose-derived 
mesenchymal stem cells with plasmids harbouring the 
improved BMP-2 sequence led to a several fold increased 
expression rate and subsequent osteogenic differentiation. 
Additionally, comparing expression kinetics of elongation 
factor 1 alpha (EF1α) promoter with a state of the art CMV 
promoter revealed significantly higher BMP-2 expression 
when under the influence of the EF1α promoter. Results 
obtained by quantification of bone markers as well as 
osteogenic assays showed reduced sensitivity to promoter 
silencing effects of the EF1α promoter in rat adipose-
derived mesenchymal stem cells. Finally, screening of 
several protein secretion signals using either luciferase or 
BMP-2 as reporter protein revealed no superior candidates 
for potential replacement of the native BMP-2 secretion 
signal. Taken together, by enhancing the exogenous 
BMP-2 expression system, low transfection efficiencies 
in therapeutic applications can be compensated, making 
safe non-viral systems even more suitable for tissue 
regeneration approaches.
Keywords: Bone morphogenetic protein, gene therapy, 
osteogenic differentiation, bone regeneration, codon 
optimisation, intron, non-viral, secretion signal.
*Address for correspondence:
Ara Hacobian,
Ludwig Boltzmann Institute for Experimental and Clinical 
Traumatology,
Donaueschingenstrasse 13,
A-1200 Vienna, Austria,
Telephone Number: +43 (0) 59393-41961,
E-Mail: ara.hacobian@trauma.lbg.ac.at
Introduction
One focus within the field of regenerative medicine is 
the reconstruction of bone defects or compensation of 
deficient regeneration. Several studies have investigated 
the practicability of applying growth factors, either in 
form of recombinant proteins or by means of gene therapy 
encoding an exogenous gene on a plasmid (Feichtinger 
et al., 2014; Kempen et al., 2010; Koh et al., 2008; Sood 
et al., 2012). Recombinant proteins used in therapeutic 
approaches generally show a short half-life at the target site 
(Alt et al., 2009; Sandhu, 2004). Therefore, delivery of up 
to mg dosages at once are required to provide a sufficient 
stimulus. As a result, these supraphysiological local 
dosages lead to increased occurrence of protein diffusion 
and side effects (Carragee et al., 2011; Glassman et al., 
2011; Shimer et al., 2009). As a promising alternative, 
gene therapy allows local and sustained release of growth 
factors. Due to this moderate and constant release, it is 
more suitable for regenerative processes compared to 
administration of high protein doses, (Bleiziffer et al., 
2007; Southwood et al., 2004). Therefore, the use of gene 
therapy in order to stimulate bone formation by introducing 
deoxyribonucleic acid (DNA) vectors encoding for 
therapeutic genes is very promising. However, compared 
to viral gene delivery methods, non-viral gene therapy 
shows generally low gene transfer efficiency, especially 
in vivo. Nevertheless, non-viral approaches do not trigger 
the host´s immune responses that much, due to lack 
of viral protein components and also have a very rare 
frequency of inserting into host genome (Martin et al., 
1999). Furthermore, there is no size limitation concerning 
coding sequence and production is cost-efficient, safe and 
easy. Taking these factors into account, non-viral delivery 
methods are considered the most suitable candidates for 
clinical translation of tissue regenerative gene therapy. 
Therefore, instead of making viral gene transfer safer, 
currently a large number of on-going attempts are focussing 
on the enhancement of non-viral approaches (Bleiziffer 
et al., 2007; Glover et al., 2005). There is still plenty of 
room for improvement of the presently available non-viral 
vectors, regarding expression rate and duration (Al-Dosari 
and Gao, 2009; Kay, 2011; Mingozzi and High, 2011; 
Wang et al., 2013). Methods for improvement of bone 
morphogenetic protein 2 (BMP-2) expression systems 
are introduced in this work in order to promote further 
development of non-viral gene delivery approaches making 
safe non-viral systems even more applicable (Fig. 1).
 Due to the ability to induce bone formation in vitro 
and in vivo (Celeste et al., 1990; Reddi, 1998; Wozney 
and Rosen, 1998), BMP-2 represents a standard growth 
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factor candidate for osteogenic gene therapy (Bonadio et 
al., 1999; Einhorn, 2003; Johnson and Urist, 2000; Loozen 
et al., 2015; Osawa et al., 2009; Tepper and Mehrara, 
2002). As such, this work focuses on the improvement 
of a BMP-2 gene expression system in different cell lines 
and rat adipose-derived mesenchymal stem cells in order 
to compensate for low non-viral gene transfer levels in 
bone regeneration. Generally, introduced approaches to 
increase BMP-2 expression were divided into three steps: 
modification of gene sequence, comparison of commonly 
used promoters, and screening for efficient protein 
secretion signals (Fig. 1). For sequence modification, 
codon optimisation and insertion of an artificial intron 
were applied. In general, different codons are preferentially 
used in different organisms, which is dependent on the 
tRNA concentration inside the cell. Codon usage plays an 
important role in the regulation of protein biosynthesis. 
Therefore, rarely used codons can slow down translation, 
whereas frequently used codons can accelerate translation 
(Cai et al., 2013; Fath et al., 2011). Also, insertion of 
introns is known to enhance transcription rates and 
messenger ribonucleic acid (mRNA) stability and export 
into the cytosol (Moabbi et al., 2012; Rose, 2008). The 
expression level of intron-less genes is often 10 to 100 
times lower than the intron-containing counterpart (Le Hir 
et al., 2003).
 Here, application of both strategies, codon usage within 
the BMP-2 gene to codons commonly used by human and 
murine cells and insertion of an artificial highly minimised 
intron, showed several fold increase in BMP-2 expression 
and osteogenic differentiation of transfected cell lines 
and rat adipose-derived stem cells compared to cells 
transfected with native BMP-2 gene. As an additional step 
to improve the BMP-2 gene expression system, strength 
and persistency of regulatory elements were investigated. 
Comparison of cytomegalovirus (CMV) promoter activity 
with the eukaryotic elongation factor 1 alpha (EF1α) 
promoter indicates limitations in efficiency of BMP-2 
expression induced by the well-established CMV promoter 
in rat adipose-derived mesenchymal stem cells.
 Finally, protein secretion sequences were another focus 
of investigation. It has been previously demonstrated that 
the expression and final yield of recombinant proteins do 
not necessarily correlate with their mRNA levels (Barnes 
et al., 2004; Knappskog et al., 2007). The secretion of 
proteins can be a limiting step if the native protein secretion 
signal is weak. The different potencies of secretion signals 
to drive protein secretion can be related to their amino 
acid composition (Futatsumori-Sugai and Tsumoto, 2010; 
Klatt and Konthur, 2012; Knappskog et al., 2007; Kober 
et al., 2013; Wen et al., 2011; Zhang et al., 2005). Based 
on this, the present study was expanded by the addition of 
screening and modification of protein secretion signals in 
order to identify signal peptide candidates with beneficial 
activity for subsequent exchange of the native BMP-2 
protein secretion sequence. Therefore, secretion sequence 
screenings were performed by transfection of cell lines with 
plasmid encoding for a luciferase reporter protein (Metridia 
luciferase) with its secretion signals selectively replaced 
with foreign signals. As second step, the Metridia luciferase 
reporter was exchanged with therapeutic BMP-2 gene and 
most potent signals were evaluated either indirectly by 
differentiation assays or by direct quantification of BMP-2 
secretion.
Materials and Methods
Optimisation of BMP-2 gene sequence
Human BMP-2 gene sequence (Gene ID: 650) was 
modified by codon optimisation using the GeneOptimizer® 
expert algorithm. Additionally, a highly truncated artificial 
intron (96 base pairs) was inserted into the open reading 
frame leading to an improved BMP-2 cassette (BMP-2-
Advanced) with highly enhanced gene expression activity. 
Additionally, a second vector was constructed harbouring 
Fig. 1. Overall workflow of performed 
steps to improve BMP-2 expression 
system. Introduced approaches to increase 
BMP-2 expression were divided into three 
steps: Modification of gene sequence 
(gene transcription and mRNA export 
rate) (1), comparison of commonly used 
promoters (gene transcription rate) (2), 
modification of secretion signal (protein 
secretion rate) (3).
193 www.ecmjournal.org
ARA Hacobian et al.                                                                                                                   Enhanced BMP-2 vector
Table 1: Overview of vectors used in this study.
Original name Description Abbreviation Backbone
pVax1-BMP-2 Conventional BMP-2 gene under CMV promoter CMVBMP-2 pVax1
pVax1-BMP-2-Advanced Optimised BMP-2 gene under CMV promoter CMVBMP-2-Adv pVax1
pEF1α-BMP-2-Advanced Optimised BMP-2 gene under EF1α promoter EF1αBMP-2-Adv pVax1
Table 2: List of the amino acid sequences of the secretion signal peptides used in this study, including their protein 
and species of origin.
Name Amino acid sequence Origin (protein) Origin (species)
Blank M - -
hBMP2 MVAGTRCLLALLLPQVLLGGAAG Bone morphogenetic protein 2 Homo sapiens
mBMP2 MVAGTRCLLALLLPQVLLG Bone morphogenetic protein 2 Mus musculus
BMP7 MGVRSLRAAAPHSFVALWAPLFLLRSALA Bone morphogenetic protein 7 Mus musculus
BMP6 MPGLGRRAQWLCWWWGLLCS Bone morphogenetic protein 6 Mus musculus
Nog MERCPSLGVTLYALVVVLGLRAAPAGG Noggin Mus musculus
Cho MPSLPAPPAPRLLLGLLLLGSRPASG Chordin Mus musculus
Gre MNRTAYTVGALLLLLGTLLPTAEG Gremlin-1 Mus musculus
Azu MTRLTVLALLAGLLASSRA Azurocidin-1 Homo sapiens
Alb MKWVTFLLLLFVSGSAFS Albumin Mus musculus
mB2a MVAGTRCLLALLLPQVLLPPASA Bone morphogenetic protein 2 (modified) Homo sapiens
mB2P MVAGTRCLLVLLLPQVLLG Bone morphogenetic protein 2 (modified) Mus musculus
TGF MPPSGLRLLPLLLPLPWLLVLTPGRPAAG Transforming growth factor beta Mus musculus
Trp 1 MNPLLILTFVAAALA Trypsinogen 1 Mus musculus
Trp 2 MNLLLILTFVAAAVA Trypsinogen 2 Mus musculus
Smo MLPARCARLLTPHLLLVLVQLSPARG SPARC-related modular calcium-binding protein 1 (SMOC1) Mus musculus
Osc MRTLSLLTLLALAALCLSDLTDA Osteocalcin Mus musculus
Osp MRIAVICFCLLGIASA Osteopontin Mus musculus
Amy MLPGLALLLLAAWTARA Amyloid beta A4 protein Homo sapiens
hVEGF MNFLLSWVHWSLALLLYLHHAKWSQA Vascular Endothelial Growth Factor A Homo sapiens
HGF MWVTKLLPALLLQHVLLHLLLLPIAIPYAEG Hepatocyte growth factor Mus musculus
Gau MGVKVLFALICIAVAEA Gaussia luciferase Gaussia princeps
Met MDIKVVFTLVFSALVQA Metridia luciferase Metridia longa
hGDNF MKLWDVVAVCLVLLHTASA Glial cell line-derived neurotrophic factor (GDNF) Homo sapiens
hBDNF MTILFLTMVISYFGCMKA Brain-derived neurotrophic factor (BDNF) Homo sapiens
ChoTXN MVKIIFVFFIFLSSFSYA Cholera enterotoxin A subunit Vibrio cholerae
hIFNa2 MALTFALLVALLVLSCKSSSVG Interferon alpha 2 Homo sapiens
vIL10 MERRLVVTLQCLVLLYLAPECGG BCRF1 protein Human herpes virus 4
Z MERRLLLLLLLLLLGPASA - Artificial
Z 2 MERRLLLLLLLLLLGPLLLLLLLLLLGPAS - Artificial
Z 3 I MERRRRRRRRRLLLLLLLLLGPASA - Artificial
Z 3 II MERRLLLLGLLLLLLGLLLLLLLLLLGPASA - Artificial
Z4R MERRRRLLFSFSCCCWDQPLP - Artificial
Gau-L2 MGVKVLFALLICIAVAEA Gaussia luciferase Gaussia princeps
Gau-L4 MGVKVLFALLLLICIAVAEA Gaussia luciferase Gaussia princeps
Gau-L6 MGVKVLFALLLLLLICIAVAEA Gaussia luciferase Gaussia princeps
Gau-L8 MGVKVLFALLLLLLLLICIAVAEA Gaussia luciferase Gaussia princeps
Gau-2L MGVKVLLFALICIAVAEA Gaussia luciferase Gaussia princeps
Gau-4L MGVKVLLLLFALICIAVAEA Gaussia luciferase Gaussia princeps
mBMP2-L6 MVAGTRCLLALLLLLLPQVLLGGAAG Bone morphogenetic protein 2 (modified) Homo sapiens
mBMP2-L8 MVAGTRCLLALLLLLLLLPQVLLGGAAG Bone morphogenetic protein 2 (modified) Homo sapiens
MRL10 MRLLLLLLLLLLGAAG Bone morphogenetic protein 2 (modified) Homo sapiens
MRPL10 MRPLLLLLLLLLLGAAG Bone morphogenetic protein 2 (modified) Homo sapiens
MRRB2 MRRMVAGTRCLLALLLPQVLLGGAAG Bone morphogenetic protein 2 (modified) Homo sapiens
the same BMP-2-Advanced cassette under the influence 
of an EF1α promoter instead a CMV promoter in order to 
test variations in promoter expression kinetics in different 
cell types (Table 1).
Secretion signal reporter vector construction
Native secretion signal of Metridia luciferase gene from 
pMetLuc2-Control vector (Clontech, USA) was removed 
by polymerase chain reaction (PCR) amplification 
and NheI/HindIII restriction sites were introduced for 
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subsequent insertion of oligonucleotides coding for 
particular protein secretion signals (Table 2). For the BMP-
2 vector, Metridia luciferase reporter was exchanged with 
advanced BMP-2 gene lacking its native protein secretion 
signal.
Cell culture and reagents
C2C12 mouse muscle myoblast precursor cell line 
(DSMZ, Germany, #ACC565) was cultured in Dulbecco´s 
Modified Eagles Medium (DMEM, Sigma Aldrich, USA) 
high glucose (4.5 g/L glucose), supplemented with 2 mM 
L-glutamine (Sigma Aldrich, USA) and 5 % foetal calf 
serum (FCS, Sigma Aldrich, USA). C3H/10T1/2 (ATCC® 
CCL-226™, USA) mouse embryonal cells and chinese 
hamster ovary (CHO) cell line (ATCC® CCL-61™, USA) 
were cultivated under same conditions except with 10 % 
foetal calf serum.
Isolation and cultivation of rat adipose-derived 
mesenchymal stem cells
Epididymal fat pads of male rats (Sprague-Dawley, 
Charles River, Germany) were minced and incubated in 
2 % collagenase (Biochrom, Germany). Digestion was 
stopped by addition of culture medium (PAA, Austria) 
containing 10 % FCS and tissue remnants were filtered 
through 100 µm cell strainers (BD Falcon, Germany), 
followed by centrifugation (seven minutes at 400 × g). 
The pellet containing pre-adipocytes, rat adipose-derived 
mesenchymal stem cells (rADSC) and stromal cells was 
washed with phosphate buffered saline (PBS) (PAA, 
Austria) and centrifuged at 400 × g. The resulting rADSCs 
isolated from adipose tissue were seeded on T75 cell 
culture flasks (PAA, Austria) for expansion. After isolation, 
rADSCs were cultivated using standard cell culture 
conditions (37 °C, 5 % CO2) in DMEM (high glucose, PAA, 
Austria) supplemented with 10 % FCS (PAA, Austria), 
200 µM L-glutamine and 1 % antibiotics (PAA, Austria). 
For expansion, cells were cultivated in cell culture flasks 
(PAA, Austria) with an initial seeding density of 3 × 103 
cells / cm2. At a confluence of 80-90 %, cells were split 
with Accutase™ (PAA, Austria). Final verification was 
performed with rADSCs at passage number two by flow 
cytometry using haematopoietic markers (CD14, CD34, 
CD45) and mesenchymal markers (CD73, CD90 CD105) 
(data provided in the supplementary material). Isolated 
rADSCs were derived from five separate donors pooled 
together. All cell transfections were conducted at passage 
number three.
Cell transfection
Cells were seeded into 24-well plates at a cell density of 
0.25 × 105/cm2 24 h before transfection. The next day, 
the plasmid was incubated with transfection reagent in 
serum-free medium for 15 min. Target cells in growth 
medium containing 5 % FCS were transfected with 1 µg of 
indicated plasmid using 3 µL of Peqfect (Peqlab, Germany) 
transfection reagent. Following this, medium was 
exchanged with fresh growth medium 3 h post transfection. 
No osteogenic media was used in any experiment. Same 
cell densities and transfection procedures were used 
for all tested cells including rADSCs. Applied amounts 
and ratios of DNA and transfection reagent are based on 
previously performed optimisation screenings aiming 
for highest transfection efficiency and low toxicity (data 
provided in the supplementary material). Data sets were 
normalised with regard to transfection performed by 
Metridia luciferase reporter vector.
Alkaline phosphatase assay
Cells transfected with the indicated BMP-2 plasmid were 
lysed with 100 µL lysis buffer consisting of alkaline 
phosphatase (ALP) buffer (0.5 M 2-Amino-2-Methyl-
1-Propanol, 2 mM magnesium chloride, pH 10.3) 
containing 0.5 % Triton X-100 and incubated for 1 h 
at room temperature. Enzymatic activity was quantified 
in supernatants after centrifugation by adding 20 mM 
p-nitrophenylphosphate in 50 µL ALP buffer as substrate. 
The reaction was stopped after 20 min with 50 µL of 
0.2 M NaOH. The conversion of p-nitrophenylphosphate 
to p-nitrophenol by ALP was quantified by its absorbance 
at 405 nm. Depicted ALP activities are referred to nmol 
of p-nitrophenol liberated per minute.
 Variations of time points for ALP quantification using 
different cell types were based on previously observed 
distinct differentiation kinetics. Therefore, different starting 
points of ALP quantification were chosen, according to the 
cell type´s specific differentiation dynamic. ALP activity 
was measured 8 d (C2C12), 14 d (C3H/10T1/2) and 21 d 
(rADSCs) post transfection.
Cell viability assay
Cytotoxicity of plasmids in combination with the transfection 
reagent was evaluated by (3- (4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium), MTS assay (Promega, Madison, USA). 
C3H/T101/2 cells (0.25 × 106/cm2) in 1 mL of DMEM 
high glucose supplemented with 10 % FCS were seeded 
in 24-well plates and transfected with indicated plasmids 
(1 µg). Control was performed by incubating with 0.9 % 
Triton X-100. After 24 h, cells were washed with 1 × PBS 
and 5 mg/mL MTS reagent in 1 × PBS (50 μL/well) and 
100 µL fresh medium was added. After 1 h of incubation 
at 37° C, the absorbance at 490 nm was determined with 
a plate reader (POLARstar Omega, BMG LABTECH, 
Austria) (Data Analysis Software: MARS 2.30 R2).
Alizarin red staining
rADSCs transfected with the indicated BMP-2 plasmid 
were washed four weeks post transfection and subsequently 
fixed with 70 % ethanol at −20° C for 1 h. Subsequent 
staining of calcium deposits was performed by incubation 
of cells with filtered 2 % Alizarin Red solution (Sigma 
Aldrich, UK) (pH 4.2) for 10 min. Absorbance of the 
centrifuged supernatant was determined at 405 nm with 
a plate reader (POLARstar Omega, BMG LABTECH, 
Austria) (Data Analysis Software: MARS 2.30 R2).
Real time quantification
All cell types used in this study were harvested and total 
Ribonucleic acid (RNA) was extracted using Trifast 
reagent (Peqlab, Germany). RNA concentrations were 
determined using a Hitachi U-5100 photometer (Metrohm 
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Inula GmBH, Austria) and the complementary DNA 
(cDNA) was synthesised from the total RNA (2 µg) using 
a EasyScript™ cDNA Synthesis Kit (abmGood, Canada). 
Subsequently, the cDNA was added to real-time PCR mix 
using a KAPA SYBR Fast Universal (Peqlab, Germany). 
Each real-time PCR reaction consisted of 4 μL of diluted 
RT product (40 ng), 10 μL KAPA SYBR Fast Universal 
and specific primer pairs (250 nM) in a total volume of 
20 μL. The reactions were performed on a C1000 / CFX96 
(Biorad, Germany) cycler using a 3 step protocol. The fold 
change in the mRNA levels of each gene was calculated 
using samples (2^−(dCt)) divided by mean (2^−(dCt)) of 
control group. The housekeeping gene glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) served for 
normalisation. All PCR primers were synthesised by 
Microsynth (Switzerland).
Metridia luciferase assay
50 µL of supernatant of transfected cells were removed 
at indicated time points for subsequent quantification of 
the secreted Metridia luciferase (Metridia longa) using 
coelenterazine substrate (NanoLight Technology, USA) 
using a Polar Star Omega Luminometer (BMG Labtech, 
Germany).
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) was 
performed according to the DuoSet ELISA development 
system (R&D Systems, USA). Mouse anti-human capture 
antibodies were used on supernatants collected from 
CHO cells 5 d post transfection with various BMP-2 gene 
containing constructs (Fig. 4).
Statistical analysis
Averaged data is presented as means ± SD. Data sets 
were tested for gaussian distribution using Kolmogorov-
Smirnov test (with Dallal-Wilkinson-Lillie for p value). 
Subsequent comparison between multiple data groups was 
performed by one-way ANOVA followed by Tukey post-
test analysis. All statistical analyses were performed using 
GraphPad Prism 5 software. Differences were considered 
significant at p < 0.05.
Results
Enhanced expression and osteogenic differentiation 
of various cell types mediated by improved BMP-2 
gene sequence
BMP-2 gene cassette was modified using codon 
optimisation and by inserting a highly truncated artificial 
intron into the coding sequence (BMP-2-Advanced). 
Induction of osteogenic differentiation mediated by 
different BMP-2 gene constructs was compared by ALP 
assay measurement. Overall, comparison showed several 
fold increase in ALP activity in different target cells 
mediated by optimised BMP-2 gene (BMP-2-Advanced) 
compared to conventional BMP-2 gene. In more detail, 
transfection of C2C12 myoblast cell line with plasmid 
containing the BMP-2-Advanced cassette under the 
influence of either CMV or EF1α promoter showed over 
five-fold increase in ALP activity compared to the plasmid 
containing conventional BMP-2 gene (Fig. 2). Cell 
transfection with plasmids harbouring the improved BMP-
2 cassette triggered several fold higher ALP activities for 
pluripotent C3H/10T1/2 and rADSCs. Viability assay was 
performed in C3H/10T1/2 cells 24 h post transfection and 
showed no significant toxic effects of transfection method 
in combination with applied plasmids compared to cells 
transfected with GFP plasmid or to untransfected control 
(Fig. 2). Furthermore, rADSCs transfected with BMP-2-
Advanced gene under the control of EF1α promoter showed 
higher ALP activities in these cells compared to the CMV 
promoter construct. Mineralisation assay based on alizarin 
Fig. 2. Comparison of osteogenic differentiation of target cells induced by various vector constructs expressing bone 
morphogenetic protein 2 (BMP-2). Cells were transfected with either pVax1-BMP-2, pVax1-BMP-2-Advanced or 
pEF1α-BMP-2-Advanced plasmid (1 µg/mL), respectively. Quantification of induced ALP activity was measured 
after 8 d (C2C12), 14 d (C3H/10T1/2) and 21 d (rADSCs) post transfection showed several fold increase compared 
to conventional the BMP-2 vector. Additionally, pluripotent cell types showed increased osteogenic differentiation 
when transfected with the improved BMP-2 cassette under the influence of the EF1α promoter compared to same 
BMP-2 cassette under the influence of the CMV promoter. Viability assay was performed in C3H/10T1/2 cells 24 h 
post transfection using untransfected cells as control. Transfection control was performed using pMax-GFP plasmid 
(Lonza/Amaxa, USA. Averaged data are presented as means ± SD determined with four replicates, experiment was 
performed twice, p < 0.001).
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red staining underlined the observations of osteogenic 
differentiation of the various tested target cells previously 
quantified by ALP assay (Fig. 2). For further analysis, a 
kinetic experiment was conducted to obtain information 
about duration of gene expression mediated by different 
promoters. Interestingly, quantification of secreted BMP-2 
revealed constant expression of protein induced by both 
tested promoters over a period of 8 d. In conclusion, cell 
transfection with the improved BMP-2 gene cassette 
showed a significantly higher activity in all tested cell types 
compared to the conventional BMP-2 gene, regardless of 
used cell and promoter type.
 A similar phenotype was observed after verification 
of osteogenic differentiation in transfected cells by 
quantitative real time analysis using bone specific markers 
such as Osteocalcin, Runx2, Osteopontin (Fig. 4). Again, 
advanced BMP-2 vector constructs showed significantly 
higher gene expression activity of osteogenic markers in all 
tested cell types compared to the native BMP-2 gene. Here 
too, an increased osteogenic differentiation potential of 
rADSCs induced by the BMP-2-Advanced cassette under 
the control of the EF1α promoter was observed compared 
to the CMV promoter construct.
 In order to directly link observed enhanced osteogenic 
differentiation of target cells to the amount of BMP-2 
secretion, secretome of various transfected cell types was 
examined in parallel. Quantification of secreted BMP-2 
protein 5 d post transfection revealed a linear relation 
to the measured ALP activity and therefore the stage of 
overall osteogenic differentiation of transfected target cells. 
Improved BMP-2 gene showed several fold better BMP-2 
secretion than the native BMP-2 gene, and here too, EF1α 
promoter displayed significantly higher activity in rADSCs 
than its CMV counterpart (Fig. 5).
 Additionally, in order to quantify the absolute BMP-2 
secretion, candidate plasmids were also transfected into 
CHO cells. Due to the lack of BMP receptors in CHO 
cells, auto- and paracrine re-uptake of secreted BMP-2 
was circumvented and absolute protein secretion was 
determined. CHO cells transfected with the improved 
BMP-2 gene plasmid showed several fold higher BMP-2 
secretion compared to conventional BMP-2 gene (Fig. 
5). Interestingly, the EF1α promoter construct again 
showed significantly better activity compared to the CMV 
promoter plasmid, a phenomenon, which was previously 
observed only in rADSCs. Finally and surprisingly, an 
8 d experiment in C3H/10T1/2 cells covering BMP-2 
expression kinetics showed no significant differences.
Comparison of various protein secretion signals 
showed superior potency of native protein secretion 
signal of BMP-2
As final part of this work, different secretion signals were 
tested for possible exchange of the secretion signal of 
BMP-2 aiming for increase in protein secretion levels. 
Amongst the candidates, signals derived from inhibitory 
proteins (Noggin, Chordin, Gremlin-1) as well as 
from activator proteins (Osteopontin, BMP-6, BMP-7) 
expressed during osteogenic differentiation were included 
in the experiments.
 As a first step, the native secretion signal of Metridia 
luciferase was replaced with the secretion signal of the 
selected candidates. Subsequently, C2C12 cells were 
transfected with particular vector constructs and secreted 
Metridia luciferase was measured after 3 d (Fig. 6A). 
Quantification by Metridia luciferase assay, normalised 
with regard to transfection efficiency, revealed that 
the secretion signal sequence of BMP-2 as well as the 
signal sequences of all selected inhibitory factors of the 
osteogenic pathway (Noggin, Chordin, Gremlin-1) showed 
highest potential in mediating protein secretion in C2C12 
cells, whereas in contrast the secretion signal derived from 
BMP-7 displayed relatively weak potency.
 Furthermore, a number of selected secretion signals 
were transferred to BMP-2 gene and exchanged with its 
original secretion signal (Fig. 6B). Additionally, further 
signals derived from different organisms were chosen 
in order to test for their potency to mediate BMP-2 
secretion, amongst them, signals derived from cholera 
enterotoxin A subunit and viral interleukin-10 protein. In 
general, the selected secretion signals showed comparable 
potency to mediate secretion of BMP-2 as well as for 
Metridia luciferase reporter. One exception included the 
signal sequence of Trypsin-1, which was unable to retain 
same potency as previously displayed for the Metridia 
luciferase reporter. The signal sequence derived from 
BMP-7 protein was too weak to maintain sufficient BMP-
Fig. 3. Quantification of mineralisation of rADSCs after 
transfection with various vector constructs expressing 
bone morphogenetic protein 2 (BMP-2). rADSCswere 
transfected with either pVax1-BMP-2, pVax1-BMP-2-
Advanced or pEF1α-BMP-2-Advanced plasmid (1 µg/
mL), respectively. Additionally, untransfected cells 
served as reference (control). Alizarin red staining 
was performed four weeks post transfection. Cells 
transfected with enhanced BMP-2 cassette showed 
higher induction of mineralisation compared to cells 
transfected with conventional BMP-2 plasmid. Averaged 
data are presented as means ± SD, determined with four 
replicates, p < 0.001).
Mineralisation of rADSC
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2 secretion in order to induce osteogenic differentiation 
of C2C12 precursor cells. In summary, the original 
secretion sequences of human BMP-2 mediated superior 
and very reliable protein secretion of either Metridia 
luciferase reporter or BMP-2 gene, respectively. None 
of the substituted secretion signals showed significant 
improvement in protein secretion compared to secretion 
mediated by native BMP-2 signal.
Modifications of the BMP-2 secretion signals resulted 
in a decreased potency
Further attempts to improve the secretion sequence of 
BMP-2, either by insertion of additional hydrophobic 
amino acids, or by addition of positively charged 
N-terminal amino acids, led to a decreased protein secretion 
capacity. Only an exchange of the terminal cleavage site 
of the BMP-2 secretion signal (mB2a) showed significant 
improvement of potency compared to the original BMP-2 
secretion signal.
 Some attempts to improve another secretion signal 
derived from Gaussia luciferase, which was previously 
classified as a potent secretion signal, caused an increase 
in the secretion levels comparable to protein secretion 
levels mediated by the native BMP-2 secretion signal 
(Fig. 7). Especially the insertion of additional hydrophobic 
amino acids at the end of the hydrophobic core led to a 
Fig. 4. Quantitative real time analysis in different cell lines after transfection with various vector constructs expressing 
bone morphogenetic protein 2 (BMP-2). Cells were transfected with either pVax1-BMP-2, pVax1-BMP-2-Advanced or 
pEF1α-BMP-2-Advanced plasmid (1 µg/mL), respectively. Quantification of osteogenic marker genes by quantitative 
real time analysis was performed 8 d (C2C12), 14 d (C3H/10T1/2) and 21 d (rADSCs) post transfection. All osteogenic 
marker genes showed several fold increase compared to cells transfected with conventional BMP-2 vector. Additionally, 
for pluripotent cell types, transfection with advanced BMP-2 gene under the influence of the EF1α promoter showed 
higher expression of osteogenic marker genes compared to same cassette with CMV promoter, respectively. Averaged 
data are presented as means ± SD determined with four replicates, experiment was performed twice, p < 0.001).
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significant increase in potency compared to the native 
signal. Altogether, modifications on secretion signals 
resulted in either a slight improvement or complete loss 
of potency.
 Additional experiments on protein secretion kinetics 
were performed in order to observe potential protein 
secretion dynamics within the first 3 d post transfection 
in CHO cells. Obtained data showed a constant protein 
secretion induced by all secretion signals except Trypsin-1 
signal. Additionally, the data underlined previously 
evaluated high potencies of the secretion signals derived 
from BMP-2 protein, as well as its modified version 
(mB2a) and the artificially designed signal (Z) (Fig. 8). 
Interestingly, in contrast to other secretion signals, Metridia 
luciferase protein equipped with the secretion signal of 
human GDNF already showed a secretion stop after 24 h. 
Subsequent toxicity assay showed no difference in viability 
of these cells compared to cells transfected with other 
signal sequences.
Discussion
Due to the fact that low gene delivery and subsequent 
low expression of the introduced genes is given (Glover 
et al., 2005), the application of non-viral gene transfer 
has been ignored for a long time. Nevertheless, due to 
its low immunotoxicity, non-viral vectors have regained 
significant attention in the past years. Advances in 
efficiency, specificity, duration of gene expression and 
safety led to a rising number of non-viral vector products 
entering clinical trials. However, there is still plenty of 
room for improvement of currently available non-viral 
vectors regarding expression rate and duration (Al-Dosari 
and Gao, 2009; Kay, 2011; Mingozzi and High, 2011; Wang 
et al., 2013). To promote further development of non-viral 
gene delivery approaches, non-viral expression systems 
were designed and tested for bone tissue engineering and 
regeneration. The described strategies can be transferred 
to any other gene expression system to increase specific 
gene expression.
Fig. 5. Comparison of bone morphogenetic protein 2 (BMP-2) expression rate by ELISA analysis in different cell 
lines after transfection with various BMP-2 vector constructs Various cell types were transfected with either pVax1-
BMP-2, pVax1-BMP-2-Advanced or pEF1α-BMP-2-Advanced plasmid (1 µg/mL), respectively. Quantification of 
secreted BMP-2 was determined by ELISA either 5 d post transfection (A), or every second day over a time period 
of 8 d (B). Averaged data is presented as means ± SD determined with six replicates, experiment was performed 
twice, p < 0.001 (A). Kinetic experiment (B) was performed once with three replicates.
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 Several studies have successfully exploited codon 
optimisation to increase yield in eukaryotic cells for in 
vitro production of recombinant proteins (interleukin 2 (Ou 
et al., 2014), coagulation factor VIII (Ward et al., 2011)), 
vaccination (Frelin et al., 2004; Ko et al., 2005), and gene 
replacement therapy such as microdystrophin (Foster et al., 
2008) and PhiC31 recombinase (Raymond and Soriano, 
2007). However, codon optimisation on growth factor 
genes for application in tissue regeneration has great 
potential, but has mostly been unexploited yet. Concerning 
BMPs, a single recombinant protein production study 
exists describing a five-fold enhanced expression of BMP-
4 in Pichia pastoris (Huang et al., 2014), underlining 
untouched opportunities improving the outcome for 
gene therapeutical approaches. In our case, a several fold 
increase in osteogenic response in vitro was achieved by 
modifying the BMP-2 gene sequence as mentioned above, 
which is crucial when low transfection efficiencies have to 
be compensated, predominantly occurring in applications 
in vivo. Codon optimisation of the BMP-2 gene to adjust 
codon usage frequency within the mammalian organism 
as well as the addition of an artificial short intron element 
(intron) derived from alpha globin gene, resulted in 
several-fold higher osteogenic response of target cells 
after transfection, indicating a higher expression rate of 
the modified BMP-2 sequence compared to the unmodified 
gene. These higher production rates were verified by 
quantification of secreted BMP-2 levels produced by 
CHO cells. The positive effect of codon optimisation on 
gene expression levels is not exclusively explainable by 
codon usage and particular tRNA levels of the respective 
organisms. Alteration of nucleotide sequence during codon 
optimisation process would eradicate potential binding 
sites of endogenous regulatory and transcription factors 
which could hinder efficient transcription.
 Apart from codon optimisation, the major reason for 
enhanced gene expression in our study is assumed to be 
based on the subsequent insertion of an artificial intron 
into the coding region of the gene. Underlying mechanisms 
for increased expression are not yet fully understood. One 
explanation is that introns contain sequence motifs that 
stimulate the elongation complex during transcription. 
This theory, however, does not apply to our introduced 
highly minimised intron, due to its randomly designed 
Fig. 6. Selected protein secretion signals were tested for their ability to drive protein secretion in C2C12 cells. The 
native secretion signal of Metridia luciferase was replaced with the respective secretion signal of the selected candidates 
(Table 2). C2C12 cells were transfected with the particular vector constructs and secreted Metridia luciferase was 
measured 3 d post transfection (A). Secretion signal screen was translated into an osteogenic system. The native 
secretion signal of human BMP-2 gene was replaced with the respective secretion signal of the selected candidates 
(Table 2). C2C12 cells were transfected with the particular vector constructs and ALP activity was measured 6 d 
post transfection (B). None of the substituted secretion signals showed significant improvement in protein secretion 
compared to secretion mediated by native BMP-2 signal. Averaged data are presented as means ± SD determined 
with six replicates).
Neg: without secretion signal, BMP: Bone morphogenetic protein, Nog: Noggin, Cho: Chordin, Gre: Gremlin-1, 
Azu: Azurocidin-1, Alb: Albumin, TGF: Transforming growth factor beta, Trp1: Trypsin-1, Trp2: Trypsin-2, Smo: 
SPARC related modular calcium binding 1, Osc: Osteocalcin, Osp: Osteopontin, Amy: Amyloid beta, VEGF: Vascular 
Endothelial Growth Factor A, HGF: Hepatocyte growth factor, vIL10: Viral Interleukin-10, Z: in silico designed, 
BDNF: Brain-derived neurotrophic factor, GDNF: Glial cell line-derived neurotrophic factor, IFNa2: Interferon 
alpha 2, ChoTXN: Cholera enterotoxin A subunit, SS: secretion signal.
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Fig. 7. Modification of protein secretion signals of Gaussia luciferase and human bone morphogenetic protein 2 
(BMP-2) gene. The native secretion signal of human BMP-2 was replaced with the respective secretion signal derived 
from modifications of the signals of Gaussia luciferase and human BMP-2 gene. C2C12 cells were transfected with 
the particular vector constructs and ALP activity was measured 6 d post transfection in order to test the efficiency 
of the modified signals to drive BMP-2 secretion. Averaged data is presented as means ± SD determined with six 
replicates, experiment was performed twice, p < 0.001.
Fig. 8. Selected protein secretion signals were tested for their ability to drive protein secretion in CHO cells. The 
native secretion signal of BMP-2 gene was replaced with the respective secretion signal of the selected candidates. 
CHO cells were transfected with the particular vector constructs and secreted BMP-2 protein was measured 24 h, 48 h 
and 72 h post transfection (A). In order to evaluate net secretion, culture medium was replaced with fresh medium 
24 h prior taking aliquots for subsequent BMP-2 quantification by ELISA. Averaged data are presented as means 
± SD determined with six replicates.
Neg: without secretion signal, BMP: Bone morphogenetic protein, Ori: original unmodified (without insertion of 
restriction sites), Nog: Noggin, Cho: Chordin, Gre: Gremlin-1, TGF: Tissue growth factor beta, Trp1: Trypsin-1, 
Osp: Osteopontin, vIL10: viral Interleukin-10, Z, Z4R: in silico designed, mB2a: modified bone morphogenetic 
protein 2, BDNF: Brain-derived neurotrophic factor, GDNF: Glial cell line-derived neurotrophic factor, IFNa2: 
Interferon alpha 2, ChoTXN: Cholera enterotoxin A subunit, SS: secretion signal.
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artificial sequence. A more likely explanation is, given 
that transcription and splicing procedures are executed 
simultaneously, splicing factors improve transcription 
by reducing transcription-associated genome instability 
(Moabbi et al., 2012; Niu and Yang, 2011; Rose, 2008).
 With regards to regulatory elements, cells transfected 
with the BMP-2-Advanced gene under the control of EF1α 
promoter showed higher expression activities compared to 
cells transfected with the CMV promoter construct. Also, 
when under the influence of the EF1α promoter, increased 
osteogenic differentiation was observed in rADSCs. This is 
most likely caused either by enhanced BMP-2 expression 
activity or due to possible silencing of the CMV promoter. 
This active shut down of transcription is mediated by 
inhibitory factors or the lack of specific transcription 
factors essential for gene expression. rADSCs might have 
the (co)-factors necessary for full transcriptional activity 
of cellular promoters, such as the EF1α promoter, which 
may operate more ubiquitously. A similar gene expression 
phenotype was observed previously by Chung et al. in 
transiently transfected mouse embryonic stem cells (Chung 
et al., 2002). The group showed that both the EF1α and 
chicken β-actin promoter strongly triggered reporter gene 
expression while the viral CMV promoter was largely 
inactive but became active upon differentiation of the stem 
cells to neuronal precursor cells. Furthermore, observed 
results go in line with the results obtained by another study, 
underlining the susceptibility of the CMV promoter to 
specific cell types, among them mesenchymal stem cells 
(Qin et al., 2010). Interestingly, quantification of BMP-2 
release in C3H/10T1/2 cells over an 8 d period revealed no 
significant difference in gene expression kinetics of both 
promoters.
 However, it has been demonstrated that the yield of 
recombinant proteins does not necessarily correlate with 
their mRNA levels (Barnes et al., 2004; Knappskog et al., 
2007). Regarding the application of genes encoding for 
extracellular growth factors, inefficient protein secretion 
can be an additional bottleneck. Therefore, this study 
further focused on the identification of more potent signal 
sequences mediating increased protein secretion for gene 
therapeutic applications in bone tissue regeneration. Human 
BMP-2 was used as a standard growth factor candidate for 
osteogenic gene therapy (Bonadio et al., 1999; Einhorn, 
2003; Johnson and Urist, 2000; Loozen et al., 2015; Osawa 
et al., 2009; Tepper and Mehrara, 2002). Various secretion 
signals as well as their modifications derived either from 
osteogenic factors or previously documented resources 
were compared amongst each other to mediate secretion 
of Metridia luciferase or human BMP-2 protein.
 Compared to other protein secretion signals, the signal 
sequence of the BMP-2 gene showed superior ability to 
mediate secretion of either Metridia luciferase reporter 
protein or BMP-2. Interestingly, the secretion signal 
derived from BMP-7, a protein, which is used to form 
heterodimers with BMP-2 in equimolar ratios, displayed 
relatively weak potencies compared to the BMP-2 signal. 
Additional modifications of the BMP-2 signal sequence 
led to loss of potency in secretion when altering the length 
of the sequence rather than altering specific amino acids. 
Therefore, previously described observations of enhanced 
potency of a secretion signal by increasing the basicity 
and hydrophobicity of the amino acid composition (Zhang 
et al., 2005) are in contrast to our results obtained after 
modifications of the BMP-2 secretion signal. One of the 
few candidates which displayed a potency to mediate 
protein secretion comparable to, or higher than, the native 
BMP-2 signal sequence was a signal sequence designed 
in silico (Z), consisting of a typical short basic region 
followed by a hydrophobic area combined with an in silico 
designed cleavage site. Finally, the secretion signal of 
Gaussia luciferase, which was previously shown to have 
high activity to mediate protein secretion (Knappskog et 
al., 2007), was only comparable to BMP-2 signal potency 
after additional modifications were performed at the 
hydrophobic domain. In conclusion, attempts to enhance 
secretion signal of BMP-2 were mostly unsuccessful due 
to the strength of the existing native signal. Nevertheless, 
based on the new insights the signal sequence of BMP-
2 is a promising candidate to increase protein secretion 
by replacing native sequences of other proteins of 
interest, such as growth factors in gene therapeutic or 
biotechnological approaches.
Conclusion
In this work, we have introduced modifications to 
BMP-2 expression systems in order to compensate for 
poor transfection efficiencies in non-viral gene transfer, 
successfully making these safe systems even more 
applicable for tissue engineering approaches. First, it 
was shown that codon optimisation of BMP-2 gene, as 
well as insertion of an intron, resulted in enhanced BMP-
2 expression and osteogenic differentiation in vitro. In 
rADSCs, the osteoinductive effect was further enhanced 
by replacement of the viral state of the art promoter (CMV) 
with a potent mammalian promoter (EF1α). Finally, it was 
revealed that the native BMP-2 secretion signal shows high 
efficacy in mediating protein secretion. Therefore, this 
method, as well as the potent BMP-2 secretion sequence 
itself, offer additional options to consider in improving 
poor protein expression.
 Altogether, data obtained from our study encourage us 
to further push investigations on transferring this approach 
to in vivo settings.
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Discussion with Reviewers
Reviewer I: What is the particular advantage of gene 
delivery when compared to recombinant protein delivery 
in this type of application?
Authors: Recombinant BMP-2 has a short half-life 
at the target site. Consequently, it requires delivery 
of up to mg dosages at once to provide a sufficient 
stimulus to induce osteogenic differentiation and bone 
formation. These supraphysiological local dosages lead 
to increased occurrence of protein diffusion and side 
effects. Gene therapy as a way to locally administer BMP-
2 can overcome the use of high protein doses due to the 
moderate but sustained release of protein. Since permanent 
expression of growth factors is undesirable in regenerative 
processes, non-viral transient and local gene expression is 
more suitable for this application.
 An additional advantage of gene therapy is the 
increased biocompatibility of expressed BMP-2. The 
protein is produced de novo by host cells and not by 
xenogenous cells, e.g. chinese hamster ovary cells or yeast. 
This way, post-translational modifications such as host 
specific glycosylation patterns are more compatible with 
the target tissue.
Reviewer I: What are the potential risks associated with 
non-viral gene delivery, and how are they mitigated by 
proper plasmid design?
Authors: Although non-viral gene delivery is significantly 
safer compared to viral vector systems, occurrence of 
insertional mutagenesis can still occur. Regarding safety 
of plasmids, the FDA Center for Biologics Evaluation 
and Research (CBER) has listed some points to follow 
in the document, “Points to Consider on Plasmid DNA 
Vaccines for Preventive Infectious Diseases Indications” 
(Docket no. 96N-0400). In general, all sequences except 
the ones required for replication in E. coli and for 
expression of recombinant protein in mammalian cells 
should be removed. This reduces DNA sequences with 
possible homology to the human genome and minimises 
the possibility of chromosomal integration. Furthermore, 
the gene of interest sequence can be optimised without 
changing the final amino acid composition to further 
decrease random homology.
 Safety of plasmids can further be increased by 
introduction of specific elements controlling gene of 
interest expression. Beside inducible promoters, such 
as Tetracycline/Doxycycline responsive expression, 
this can be achieved by introducing tissue specific 
promoters, thereby reducing unwanted gene expression 
in other tissues. Tissue specific gene expression can also 
be accomplished by insertion of target sequences for 
endogenous microRNAs. These miRNA target sequences 
within the plasmids expression cassette can be used to 
regulate transgene expression according to tissue, lineage 
and differentiation state of target cells. (Brown et al., 2007) 
have combined two miRNA target sites to restrict transgene 
expression to a specific cell type in the liver [1]. Therefore, 
miRNA-regulated vectors can also lead to safer and more 
effective therapeutic applications.
 Another aspect to consider is toxicity of non-viral 
shuttle systems, such as polycations and cationic lipids. 
Although significantly less immunogenic compared to 
viral systems, toxicity (e.g. accumulation in the liver, 
interactions with blood components) is still a drawback. In 
general, DNA/carrier complexes have to expose an overall 
positive net charge in order to interact with negatively 
charged cell surface and promote endocytotic uptake. 
This charge can interact with other systemic components 
resulting in unwanted side effects. As a rule of thumb, the 
204 www.ecmjournal.org
ARA Hacobian et al.                                                                                                                   Enhanced BMP-2 vector
less the positive net charge, the safer the delivery system, 
but with respect to decreased transfection efficiency. To 
avoid the necessity of electrostatic contact, one alternative 
includes the introduction of gene transfer systems based 
on receptor/ligand interactions (e.g. transferrin).
Reviewer II: Isolation and cultivation of rADSC. The 
authors use epididymal fat to perform the isolation of 
mesenchymal stem cells. The authors also stated that the 
characterisation of isolated cells was performed by FACS 
for the standard markers: CD34, CD45, CD73, CD90, 
CD105 etc. Please provide the FACS characterisation of the 
isolated cells as supplementary material. This is important 
as it has been reported that ADSCs from epididymal fat 
differ substantially in terms of morphology and surface 
markers from the ones isolated from liposuction or 
abdominal fat tissue.
Authors: FACS characterisation data of isolated ADSCs 
is provided as supplementary material. rADSC specific 
(CD73, CD90, CD105) as well as haematopoietic markers 
as a negative control (CD14, CD34, CD45) were used to 
characterise the isolated cells according to (Dominici et 
al., 2006).
Reviewer II: Fig. 7 shows an ELISA quantification of 
BMP-2 after the native secretion signal was replaced with 
the secretion signal of a number of selected candidates. Do 
such modifications affect the ability of antibodies to bind 
BMP-2 with the same efficacy, compromising the reliability 
of the assay? Can the authors please comment on this?
Authors: During conventional protein secretion, the 
signal sequence of secretory proteins is immediately 
cleaved from the nascent (denatured) polypeptide by signal 
peptidase once it has been translocated into the membrane 
of the endoplasmic reticulum (ER). BMP-2 with replaced 
secretion signals is subject to the same secretion procedure. 
Therefore, all BMP-2 proteins, even when equipped with 
different secretion signals, consist of the same amino acid 
sequence and undergo same folding processes in equal 
conditions inside the ER. We therefore conclude that 
secreted BMP-2 proteins have identical conformation and 
hence are recognised and bound by antibodies with same 
affinities during ELISA.
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